Wright, L. E., Harhash, A. A., Kozlow, W. M., Waning, D. L., Regan, J. N., She, Y., . . . Guise, T. A. (2016). Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. Oncotarget.

Wright, Laura E., et al. "Aromatase Inhibitor-induced Bone Loss Increases the Progression of Estrogen Receptor-negative Breast Cancer in Bone and Exacerbates Muscle Weakness in Vivo." Oncotarget 2016.

Wright, Laura E., et al. "Aromatase Inhibitor-induced Bone Loss Increases the Progression of Estrogen Receptor-negative Breast Cancer in Bone and Exacerbates Muscle Weakness in Vivo." Oncotarget 2016.